Altergon S.A.

Also on record

Records under this name other than the patents Altergon S.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.

Back to Altergon S.A.

Patent	Title	Status	Expires	Confidence
US 7,691,411	Pharmaceutical formulae for thyroid hormones and procedures for obtaining them Formerly held In force Term ends Dec 20, 2026 · From the USPTO record	In force	Term ends Dec 20, 2026	From the USPTO record
US 7,943,668	Process for preparing a pharmaceutical composition with anti-inflammatory and analgesic activity for administration via a patch for external use, and composition thus obtained Formerly held In force Term ends May 28, 2028 · From the USPTO record	In force	Term ends May 28, 2028	From the USPTO record
US 8,252,770	Compositions comprising glycosaminoglycans of low viscosity and use of said composition in therapy of chronic cystitis Formerly held In force Term ends Dec 18, 2028 · From the USPTO record	In force	Term ends Dec 18, 2028	From the USPTO record
US 8,592,186	Biotechnological production of chondroitin Formerly held In force Term ends May 25, 2030 · From the USPTO record	In force	Term ends May 25, 2030	From the USPTO record
US 9,066,858	Pharmaceutical composition for the sublingual administration of progesterone, and method for its preparation Formerly held In force Term ends Nov 9, 2030 · From the USPTO record	In force	Term ends Nov 9, 2030	From the USPTO record
US 10,266,611	Hybrid Cooperative Complexes of Hyaluronic Acid Formerly held In force Term ends May 2, 2032 · Medium confidence	In force	Term ends May 2, 2032	Medium confidence
US 9,314,435	Stable formulations of antiplatelet agents, omega-3 fatty acids and amylose in soft gelatin capsules Formerly held In force Term ends Dec 4, 2032 · From the USPTO record	In force	Term ends Dec 4, 2032	From the USPTO record
US 10,675,270	Chondroitin complexes for transcutaneous absorption Formerly held In force Term ends Aug 2, 2033 · From the USPTO record	In force	Term ends Aug 2, 2033	From the USPTO record
US 10,842,883	Aqueous oral solutions of steroid hormones and hydroxypropyl-β-cyclodextrin with optimised bioavailability Formerly held In force Ends no later than Nov 22, 2033 · From the USPTO record	In force	Ends no later than Nov 22, 2033	From the USPTO record
US 10,251,846	Oral Combination for the Prevention and Treatment of Bladder, Pelvic and Urogenital Apparatus Pathologies Formerly held In force Term ends Jan 20, 2034 · High confidence	In force	Term ends Jan 20, 2034	High confidence

10 of 48 patents shown.

Pro members see all 48.

Pro members: see all 48 patents